person · Reporting owner

HAYDEN DONALD J JR

Disclosed activity across 6 companies

Tapewire entity: 17557
SEC CIK: 0001202285

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AMICUS THERAPEUTICS, INC.FOLD · Entity 51196	Director	June 07, 2018	June 11, 2018
BRISTOL MYERS SQUIBB CO(BMY) · Entity 1662	EVP and President, Americas	March 01, 2005	March 03, 2005
INSMED IncINSM · Entity 3174	Director	April 09, 2019	April 11, 2019
REGENXBIO Inc.RGNX · Entity 2211	Director	May 29, 2020	June 02, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AMICUS THERAPEUTICS, INC.

Report date June 07, 2018 · Filed June 11, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,895	Reported balance After 2018-06-07 transaction · row 1 1 source row Row 1 · 2018-06-07 · Grant · Acquired 3,081 · Balance 8,895 F1: The Restricted Stock Units will vest one year after date of grant and vested shares will be payable in common stock. One (1) Restricted Stock Unit is the equivalent of one (1) share of Amicus Therapeutics, Inc. common Stock.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.23 · Expires 2028-06-07	Direct	8,912	Reported balance After 2018-06-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-06-07 · Grant · Acquired 8,912 · Balance 8,912 F2: One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2019.

Filing footnotes · ownership attribution and instrument terms

F1: The Restricted Stock Units will vest one year after date of grant and vested shares will be payable in common stock. One (1) Restricted Stock Unit is the equivalent of one (1) share of Amicus Therapeutics, Inc. common Stock.

F2: One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2019.

BRISTOL MYERS SQUIBB CO

Report date March 01, 2005 · Filed March 03, 2005

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.10 par valueSEC Table I · non-derivative	Direct	207,649	Reported balance After 2005-03-01 transaction · row 1 1 source row Row 1 · 2005-03-01 · Grant · Acquired 16,667 · Balance 207,649 F1: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date.
Executive Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.45 · Expires 2015-02-28	Direct	100,000	Reported balance After 2005-03-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2005-03-01 · Grant · Acquired 100,000 · Balance 100,000 F3: Option is not exercisable until the earlier of (i) the closing share price of common stock achieving a price of at least 15% above the option grant price and remaining at that price for seven consecutive trading days or (ii) the ninth anniversary of the grant date. Shares underlying option vest 25% a year, on a cumulative basis, commencing one year after the date of grant.
Common Stock, $0.10 par valueSEC Table I · non-derivative	IndirectBy BMY Savings & Investment Program	4,869.72	Reported balance Holding disclosure · report date 2005-03-01 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 4,869.72 F2: Based on a plan statement as of the end of the most recent fiscal quarter.

Filing footnotes · ownership attribution and instrument terms

F1: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date.

F2: Based on a plan statement as of the end of the most recent fiscal quarter.

F3: Option is not exercisable until the earlier of (i) the closing share price of common stock achieving a price of at least 15% above the option grant price and remaining at that price for seven consecutive trading days or (ii) the ninth anniversary of the grant date. Shares underlying option vest 25% a year, on a cumulative basis, commencing one year after the date of grant.

INSMED Inc

Report date April 09, 2019 · Filed April 11, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	62,197	Ending reported balance After 2019-04-09 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-04-09 · Exercise / conversion · Acquired 6,286 · Balance 68,483 F1: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Row 2 · 2019-04-09 · Sale · Disposed 6,286 · Balance 62,197 F1: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.03 · Expires 2021-12-21	Direct	3,714	Reported balance After 2019-04-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-04-09 · Exercise / conversion · Disposed 6,286 · Balance 3,714 F2: Stock options granted on December 21, 2011 under the Company's 2000 Stock Incentive Plan. The options became exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each six month anniversary date thereafter through the fourth anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2: Stock options granted on December 21, 2011 under the Company's 2000 Stock Incentive Plan. The options became exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each six month anniversary date thereafter through the fourth anniversary of the date of grant.

REGENXBIO Inc.

Report date May 29, 2020 · Filed June 02, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.66 · Expires 2030-05-29	Direct	10,000	Reported balance After 2020-05-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-05-29 · Grant · Acquired 10,000 · Balance 10,000 F1: The option will vest in 12 equal monthly installments following May 29, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: The option will vest in 12 equal monthly installments following May 29, 2020.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Theseus Pharmaceuticals, Inc.

Report date February 14, 2024 · Filed February 14, 2024

Section 16 reporting ended · disclosed 2024-02-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-02-14 transaction · row 1 1 source row Row 1 · 2024-02-14 · Other · Disposed 10,000 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the "Effective Time") with the Issuer surviving the merger. F2: At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $4.05 per Share in cash (the "Cash Amount"), subject to any applicable withholding taxes and without interest, plus (b) one non-transferable contractual contingent value right per Share (each, a "CVR"), which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-02-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-02-14 · Disposition to issuer · Disposed 3,250 · Balance 0 F3: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share. F4: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) the Cash Amount, without interest and subject to any withholding of taxes; and (ii) one CVR for each Share subject to such Issuer RSU.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the "Effective Time") with the Issuer surviving the merger.

F2: At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $4.05 per Share in cash (the "Cash Amount"), subject to any applicable withholding taxes and without interest, plus (b) one non-transferable contractual contingent value right per Share (each, a "CVR"), which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal.

F3: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share.

F4: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) the Cash Amount, without interest and subject to any withholding of taxes; and (ii) one CVR for each Share subject to such Issuer RSU.

Vitae Pharmaceuticals, Inc

Report date October 25, 2016 · Filed October 25, 2016

Section 16 reporting ended · disclosed 2016-10-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.29 · Expires 2024-06-24	Direct	Reported balance After 2016-10-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2016-10-25 · Disposition to issuer · Disposed 18,182 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F2: This option, which is fully vested, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2024-09-23	Direct	Reported balance After 2016-10-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2016-10-25 · Disposition to issuer · Disposed 17,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3: This option, which provided for vesting in three equal annual installments following on September 24, 2014, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.43 · Expires 2025-05-27	Direct	Reported balance After 2016-10-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-10-25 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F4: This option, which is fully vested was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.62 · Expires 2026-05-25	Direct	Reported balance After 2016-10-25 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-10-25 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F5: This option, which provided for vesting in four (4) equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.

F2: This option, which is fully vested, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.

F3: This option, which provided for vesting in three equal annual installments following on September 24, 2014, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.

F4: This option, which is fully vested was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.

F5: This option, which provided for vesting in four (4) equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 02, 2018 Filed Jan 4, 2018 22:08 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionStock Options (right to buy) · Derivative	10,000	$0.00 Strike: $7.15	$0.00	Disclosure SEC source: 0001209191-18-002047 · doc4.xml · derivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2019-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2017. Read SEC document
January 02, 2018 Filed Jan 4, 2018 22:08 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	SaleCommon Stock	20,000	$15.00	$300,002.00	Disclosure SEC source: 0001209191-18-002047 · doc4.xml · nonDerivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,814 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2017. F3 · price: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.00 to $15.01. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
January 02, 2018 Filed Jan 4, 2018 22:08 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionCommon Stock	20,000	$15.00	$300,002.00	Disclosure SEC source: 0001209191-18-002047 · doc4.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2017. F2 · price: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.00 to $15.01. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document
November 14, 2017 Filed Nov 16, 2017 21:04 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $3.03	$0.00	Disclosure SEC source: 0001127430-17-000085 · edgar.xml · derivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 15,000 shares Expires 2021-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock options granted on December 21, 2011 under the Company's 2000 Stock Incentive Plan. The options became exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each six month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document
November 14, 2017 Filed Nov 16, 2017 21:04 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	15,000	$32.50	$487,500.00	Disclosure SEC source: 0001127430-17-000085 · edgar.xml · nonDerivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,131 F1 · kind: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document
November 14, 2017 Filed Nov 16, 2017 21:04 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionCommon Stock	15,000	$3.03	$45,450.00	Disclosure SEC source: 0001127430-17-000085 · edgar.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document
October 11, 2017 Filed Oct 13, 2017 16:16 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $0.85	$0.00	Disclosure SEC source: 0001562180-17-003262 · primarydocument.xml · derivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,100 Underlying: Common Stock · 20,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 354,100 shares, became exercisable as follows: 237,269 of the shares subject to the option are initial shares ("Initial Shares") and 116,831 of the shares subject to the option are contingent shares ("Contingent Shares"). 60,197 of the Initial Shares vested on September 17, 2014, 44,268 of the Initial Shares vested on September 17, 2015 and an additional 3,689 of the Initial Shares shall vest upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vest over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares vesting in 36 equal monthly installments thereafter. Read SEC document
October 11, 2017 Filed Oct 13, 2017 16:16 UTC	REGENXBIO Inc. RGNX · Entity 2211	SaleCommon Stock	20,000	$34.95	$699,000.00	Disclosure SEC source: 0001562180-17-003262 · primarydocument.xml · nonDerivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
October 11, 2017 Filed Oct 13, 2017 16:16 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionCommon Stock	20,000	$0.85	$17,000.00	Disclosure SEC source: 0001562180-17-003262 · primarydocument.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
September 27, 2017 Filed Sep 29, 2017 16:19 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $0.85	$0.00	Disclosure SEC source: 0001562180-17-003045 · primarydocument.xml · derivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,100 Underlying: Common Stock · 20,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 354,100 shares, became exercisable as follows: 237,269 of the shares subject to the option are initial shares ("Initial Shares") and 116,831 of the shares subject to the option are contingent shares ("Contingent Shares"). 60,197 of the Initial Shares vested on September 17, 2014, 44,268 of the Initial Shares vested on September 17, 2015 and an additional 3,689 of the Initial Shares shall vest upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vest over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares vesting in 36 equal monthly installments thereafter. Read SEC document
September 27, 2017 Filed Sep 29, 2017 16:19 UTC	REGENXBIO Inc. RGNX · Entity 2211	SaleCommon Stock	20,000	$32.45	$649,000.00	Disclosure SEC source: 0001562180-17-003045 · primarydocument.xml · nonDerivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
September 27, 2017 Filed Sep 29, 2017 16:19 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionCommon Stock	20,000	$0.85	$17,000.00	Disclosure SEC source: 0001562180-17-003045 · primarydocument.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
September 18, 2017 Filed Sep 19, 2017 16:20 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $0.85	$0.00	Disclosure SEC source: 0001562180-17-002983 · primarydocument.xml · derivative · entry 6 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,100 Underlying: Common Stock · 20,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 354,100 shares, became exercisable as follows: 237,269 of the shares subject to the option are initial shares ("Initial Shares") and 116,831 of the shares subject to the option are contingent shares ("Contingent Shares"). 60,197 of the Initial Shares vested on September 17, 2014, 44,268 of the Initial Shares vested on September 17, 2015 and an additional 3,689 of the Initial Shares shall vest upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vest over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares vesting in 36 equal monthly installments thereafter. Read SEC document
September 18, 2017 Filed Sep 19, 2017 16:20 UTC	REGENXBIO Inc. RGNX · Entity 2211	SaleCommon Stock	20,000	$29.95	$599,000.00	Disclosure SEC source: 0001562180-17-002983 · primarydocument.xml · nonDerivative · entry 4 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
September 18, 2017 Filed Sep 19, 2017 16:20 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionCommon Stock	20,000	$0.85	$17,000.00	Disclosure SEC source: 0001562180-17-002983 · primarydocument.xml · nonDerivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
September 15, 2017 Filed Sep 19, 2017 16:20 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $0.85	$0.00	Disclosure SEC source: 0001562180-17-002983 · primarydocument.xml · derivative · entry 5 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,100 Underlying: Common Stock · 20,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 354,100 shares, became exercisable as follows: 237,269 of the shares subject to the option are initial shares ("Initial Shares") and 116,831 of the shares subject to the option are contingent shares ("Contingent Shares"). 60,197 of the Initial Shares vested on September 17, 2014, 44,268 of the Initial Shares vested on September 17, 2015 and an additional 3,689 of the Initial Shares shall vest upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vest over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares vesting in 36 equal monthly installments thereafter. Read SEC document
September 15, 2017 Filed Sep 19, 2017 16:20 UTC	REGENXBIO Inc. RGNX · Entity 2211	SaleCommon Stock	20,000	$27.45	$549,000.00	Disclosure SEC source: 0001562180-17-002983 · primarydocument.xml · nonDerivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
September 15, 2017 Filed Sep 19, 2017 16:20 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionCommon Stock	20,000	$0.85	$17,000.00	Disclosure SEC source: 0001562180-17-002983 · primarydocument.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
September 07, 2017 Filed Sep 7, 2017 20:46 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $3.03	$0.00	Disclosure SEC source: 0001127430-17-000078 · edgar.xml · derivative · entry 9 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 15,000 shares Expires 2021-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock options granted on December 21, 2011 under the Company's 2000 Stock Incentive Plan. The options became exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document
September 07, 2017 Filed Sep 7, 2017 20:46 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	15,000	$30.00	$450,000.00	Disclosure SEC source: 0001127430-17-000078 · edgar.xml · nonDerivative · entry 6 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,131 F1 · kind: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document
September 07, 2017 Filed Sep 7, 2017 20:46 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionCommon Stock	15,000	$3.03	$45,450.00	Disclosure SEC source: 0001127430-17-000078 · edgar.xml · nonDerivative · entry 5 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document
September 05, 2017 Filed Sep 7, 2017 20:46 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $3.03	$0.00	Disclosure SEC source: 0001127430-17-000078 · edgar.xml · derivative · entry 8 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 15,000 shares Expires 2021-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock options granted on December 21, 2011 under the Company's 2000 Stock Incentive Plan. The options became exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document
September 05, 2017 Filed Sep 7, 2017 20:46 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $3.03	$0.00	Disclosure SEC source: 0001127430-17-000078 · edgar.xml · derivative · entry 7 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 15,000 shares Expires 2021-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock options granted on December 21, 2011 under the Company's 2000 Stock Incentive Plan. The options became exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document
September 05, 2017 Filed Sep 7, 2017 20:46 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	15,000	$29.50	$442,500.00	Disclosure SEC source: 0001127430-17-000078 · edgar.xml · nonDerivative · entry 4 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,131 F1 · kind: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document
September 05, 2017 Filed Sep 7, 2017 20:46 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionCommon Stock	15,000	$3.03	$45,450.00	Disclosure SEC source: 0001127430-17-000078 · edgar.xml · nonDerivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document
September 05, 2017 Filed Sep 7, 2017 20:46 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	15,000	$29.50	$442,500.00	Disclosure SEC source: 0001127430-17-000078 · edgar.xml · nonDerivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,131 F1 · kind: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document
September 05, 2017 Filed Sep 7, 2017 20:46 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionCommon Stock	15,000	$3.03	$45,450.00	Disclosure SEC source: 0001127430-17-000078 · edgar.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document
September 05, 2017 Filed Sep 7, 2017 17:37 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $0.85	$0.00	Disclosure SEC source: 0001562180-17-002913 · primarydocument.xml · derivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,100 Underlying: Common Stock · 20,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 354,100 shares, became exercisable as follows: 237,269 of the shares subject to the option are initial shares ("Initial Shares") and 116,831 of the shares subject to the option are contingent shares ("Contingent Shares"). 60,197 of the Initial Shares vested on September 17, 2014, 44,268 of the Initial Shares vested on September 17, 2015 and an additional 3,689 of the Initial Shares shall vest upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vest over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares vesting in 36 equal monthly installments thereafter. Read SEC document
September 05, 2017 Filed Sep 7, 2017 17:37 UTC	REGENXBIO Inc. RGNX · Entity 2211	SaleCommon Stock	20,000	$24.95	$499,000.00	Disclosure SEC source: 0001562180-17-002913 · primarydocument.xml · nonDerivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
September 05, 2017 Filed Sep 7, 2017 17:37 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionCommon Stock	20,000	$0.85	$17,000.00	Disclosure SEC source: 0001562180-17-002913 · primarydocument.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
June 13, 2017 Filed Jun 15, 2017 20:08 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantStock Options (right to buy) · Derivative	16,236	$0.00 Strike: $8.60	$0.00	Disclosure SEC source: 0001209191-17-040104 · doc4.xml · derivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,236 Underlying: Common Stock · 16,236 shares Expires 2027-06-13 F1 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2018. Read SEC document
June 13, 2017 Filed Jun 15, 2017 20:08 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantCommon Stock	5,814	$0.00	$0.00	Disclosure SEC source: 0001209191-17-040104 · doc4.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,814 Read SEC document
May 24, 2017 Filed May 26, 2017 17:01 UTC	REGENXBIO Inc. RGNX · Entity 2211	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $18.85	$0.00	Disclosure SEC source: 0000899243-17-014570 · doc4.xml · derivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-05-24 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 24, 2017. Read SEC document
May 17, 2017 Filed May 19, 2017 20:29 UTC	INSMED Inc INSM · Entity 3174	GrantCommon Stock	6,702	Not disclosed	Not disclosed	Disclosure SEC source: 0001127430-17-000043 · edgar.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,131 F1 · shares: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit was received as a grant on May 17, 2017, and represents a contingent right to receive one share of Common Stock. Read SEC document
May 15, 2017 Filed May 17, 2017 17:00 UTC	REGENXBIO Inc. RGNX · Entity 2211	SaleCommon Stock	8,599	$19.04	$163,724.96	Disclosure SEC source: 0000899243-17-013536 · doc4.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.65 to $19.275. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 08, 2017 Filed May 10, 2017 17:00 UTC	REGENXBIO Inc. RGNX · Entity 2211	SaleCommon Stock	10,000	$18.35	$183,500.00	Disclosure SEC source: 0000899243-17-012668 · doc4.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,599 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.10 to $18.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 01, 2017 Filed May 3, 2017 17:00 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $0.85	$0.00	Disclosure SEC source: 0000899243-17-011652 · doc4.xml · derivative · entry 4 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,382 Underlying: Common Stock · 20,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 354,100 shares, became exercisable as follows: 237,269 of the shares subject to the option are initial shares ("Initial Shares") and 116,831 of the shares subject to the option are contingent shares ("Contingent Shares"). 60,197 of the Initial Shares vested on September 17, 2014, 44,268 of the Initial Shares vested on September 17, 2015 and an additional 3,689 of the Initial Shares shall vest upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vest over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares vesting in 36 equal monthly installments thereafter. Read SEC document
May 01, 2017 Filed May 3, 2017 17:00 UTC	REGENXBIO Inc. RGNX · Entity 2211	SaleCommon Stock	25,262	$22.43	$566,626.66	Disclosure SEC source: 0000899243-17-011652 · doc4.xml · nonDerivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,599 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $22.00 to $22.925. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 01, 2017 Filed May 3, 2017 17:00 UTC	REGENXBIO Inc. RGNX · Entity 2211	SaleCommon Stock	4,738	$21.34	$101,108.92	Disclosure SEC source: 0000899243-17-011652 · doc4.xml · nonDerivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,861 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.00 to $21.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 01, 2017 Filed May 3, 2017 17:00 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionCommon Stock	20,000	$0.85	$17,000.00	Disclosure SEC source: 0000899243-17-011652 · doc4.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
April 24, 2017 Filed Apr 26, 2017 21:00 UTC	REGENXBIO Inc. RGNX · Entity 2211	SaleCommon Stock	10,000	$20.98	$209,800.00	Disclosure SEC source: 0000899243-17-010932 · doc4.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,599 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.45 to $21.425. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:33 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	$11.38 Strike: $9.62	$113,800.00	Disclosure SEC source: 0001104659-16-151944 · a4.xml · derivative · entry 4 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-05-25 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F5 · derivative.exercise_date: This option, which provided for vesting in four (4) equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:33 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	$8.57 Strike: $12.43	$85,700.00	Disclosure SEC source: 0001104659-16-151944 · a4.xml · derivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-05-27 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F4 · derivative.exercise_date: This option, which is fully vested was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:33 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerStock Option (Right to Buy) · Derivative	17,000	$13.00 Strike: $8.00	$221,000.00	Disclosure SEC source: 0001104659-16-151944 · a4.xml · derivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires 2024-09-23 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3 · derivative.exercise_date: This option, which provided for vesting in three equal annual installments following on September 24, 2014, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. Read SEC document
October 25, 2016 Filed Oct 25, 2016 16:33 UTC	Vitae Pharmaceuticals, Inc VTAE · Entity 181526	Disposition to issuerStock Option (Right to Buy) · Derivative	18,182	$15.71 Strike: $5.29	$285,639.22	Disclosure SEC source: 0001104659-16-151944 · a4.xml · derivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,182 shares Expires 2024-06-24 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F2 · derivative.exercise_date: This option, which is fully vested, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. Read SEC document
March 01, 2005 Filed Mar 3, 2005 22:33 UTC	BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662	GrantExecutive Option (right to buy) · Derivative	100,000	$0.00 Strike: $25.45	$0.00	Disclosure SEC source: 0000014272-05-000070 · hay363.xml · derivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · EVP and President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock, $0.10 par value · 100,000 shares Expires 2015-02-28 F3 · derivative.exercise_date: Option is not exercisable until the earlier of (i) the closing share price of common stock achieving a price of at least 15% above the option grant price and remaining at that price for seven consecutive trading days or (ii) the ninth anniversary of the grant date. Shares underlying option vest 25% a year, on a cumulative basis, commencing one year after the date of grant. Read SEC document
March 01, 2005 Filed Mar 3, 2005 22:33 UTC	BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662	GrantCommon Stock, $0.10 par value	16,667	$0.00	$0.00	Disclosure SEC source: 0000014272-05-000070 · hay363.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · EVP and President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,649 F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document
December 01, 2004 Filed Dec 3, 2004 21:00 UTC	BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662	Tax withholdingCommon Stock, $0.10 par value	5,174	$23.64	$122,313.36	Disclosure SEC source: 0000014272-04-000192 · hay319.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · EVP and President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,982 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. Read SEC document
March 02, 2004 Filed Mar 4, 2004 22:24 UTC	BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662	GrantOption (right to buy) · Derivative	110,000	$0.00 Strike: $28.11	$0.00	Disclosure SEC source: 0000014272-04-000071 · hay223.xml · derivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · EVP and President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock, $0.10 par value · 110,000 shares Expires 2014-03-01 F3 · derivative.exercise_date: Exercisable as to 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant. Read SEC document
March 02, 2004 Filed Mar 4, 2004 22:24 UTC	BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662	GrantCommon Stock, $0.10 par value	18,333	$0.00	$0.00	Disclosure SEC source: 0000014272-04-000071 · hay223.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · EVP and President, Americas 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,156 F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.